For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration agreement revenue | 0 | 58 | ||
| Research and development | 4,962 | 4,387 | ||
| Selling, general and administrative | 3,316 | 3,672 | ||
| Total costs and expenses | 8,278 | 8,059 | ||
| Operating loss | -8,278 | -8,001 | ||
| Total other income, net | 50 | 55 | ||
| Net loss | -8,228 | -7,946 | ||
| Basic EPS | -1.23 | -2.9 | ||
| Basic Average Shares | 6,666,943 | 2,743,828 | ||
BioCardia, Inc. (BCDA)
BioCardia, Inc. (BCDA)